These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Uremic cardiomyopathy and insulin resistance: a critical role for akt? Semple D; Smith K; Bhandari S; Seymour AM J Am Soc Nephrol; 2011 Feb; 22(2):207-15. PubMed ID: 20634295 [TBL] [Abstract][Full Text] [Related]
8. Cardiac Metabolism in Heart Failure and Implications for Uremic Cardiomyopathy. Nguyen TD; Schulze PC Circ Res; 2023 Apr; 132(8):1034-1049. PubMed ID: 37053280 [TBL] [Abstract][Full Text] [Related]
10. Deficiency of Soluble α-Klotho as an Independent Cause of Uremic Cardiomyopathy. Xie J; Wu YL; Huang CL Vitam Horm; 2016; 101():311-30. PubMed ID: 27125747 [TBL] [Abstract][Full Text] [Related]
11. Is uremic cardiomyopathy a direct consequence of chronic kidney disease? Chinnappa S; Hothi SS; Tan LB Expert Rev Cardiovasc Ther; 2014 Feb; 12(2):127-30. PubMed ID: 24404903 [TBL] [Abstract][Full Text] [Related]
12. Severe left ventricular systolic dysfunction may reverse with renal transplantation: uremic cardiomyopathy and cardiorenal syndrome. Zolty R; Hynes PJ; Vittorio TJ Am J Transplant; 2008 Nov; 8(11):2219-24. PubMed ID: 18808406 [TBL] [Abstract][Full Text] [Related]
13. Pro-oxidative priming but maintained cardiac function in a broad spectrum of murine models of chronic kidney disease. Wollenhaupt J; Frisch J; Harlacher E; Wong DWL; Jin H; Schulte C; Vondenhoff S; Moellmann J; Klinkhammer BM; Zhang L; Baleanu-Curaj A; Liehn EA; Speer T; Kazakov A; Werner C; van der Vorst EPC; Selejan SR; Hohl M; Böhm M; Kramann R; Biessen EAL; Lehrke M; Marx N; Jankowski J; Maack C; Boor P; Prates Roma L; Noels H Redox Biol; 2022 Oct; 56():102459. PubMed ID: 36099852 [TBL] [Abstract][Full Text] [Related]
14. The role of fibroblast growth factor 23 and Klotho in uremic cardiomyopathy. Grabner A; Faul C Curr Opin Nephrol Hypertens; 2016 Jul; 25(4):314-24. PubMed ID: 27219043 [TBL] [Abstract][Full Text] [Related]
15. Effects of calcimimetic combined with an angiotensin-converting enzyme inhibitor on uremic cardiomyopathy progression. Mizobuchi M; Ogata H; Hosaka N; Kumata C; Nakazawa A; Kondo F; Koiwa F; Kinugasa E; Akizawa T Am J Nephrol; 2011; 34(3):256-67. PubMed ID: 21791922 [TBL] [Abstract][Full Text] [Related]
16. Echocardiographic evaluation of left ventricular dimensions and function in chronic hemodialysis patients with cardiomegaly. Renger A; Müller M; Jutzler GA; Bette L Clin Nephrol; 1984 Mar; 21(3):164-8. PubMed ID: 6231149 [TBL] [Abstract][Full Text] [Related]
17. Uremic cardiomyopathy: an inadequate left ventricular hypertrophy. London GM; Fabiani F; Marchais SJ; de Vernejoul MC; Guerin AP; Safar ME; Metivier F; Llach F Kidney Int; 1987 Apr; 31(4):973-80. PubMed ID: 2953925 [TBL] [Abstract][Full Text] [Related]
18. Comparison of the antiremodeling effects of losartan and mirabegron in a rat model of uremic cardiomyopathy. Kovács ZZA; Szűcs G; Freiwan M; Kovács MG; Márványkövi FM; Dinh H; Siska A; Farkas K; Kovács F; Kriston A; Horváth P; Kővári B; Cserni BG; Cserni G; Földesi I; Csont T; Sárközy M Sci Rep; 2021 Sep; 11(1):17495. PubMed ID: 34471171 [TBL] [Abstract][Full Text] [Related]
19. [Cardiac manifestations of terminal kidney insufficiency. Current characterization of uremic cardiomyopathy]. Josephs W; Odenthal HJ Dtsch Med Wochenschr; 1995 Feb; 120(5):141-4. PubMed ID: 7843032 [No Abstract] [Full Text] [Related]
20. Uremic cardiomyopathy: role of circulating digitalis like substances. Mohmand B; Malhotra DK; Shapiro JI Front Biosci; 2005 Sep; 10():2036-44. PubMed ID: 15970476 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]